- Home
- RYTM vs TAC Comparison
RYTM vs TAC Comparison
Compare RYTM & TAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- TAC
- Stock Information
- Founded
- RYTM 2008
- TAC 1909
- Country
- RYTM United States
- TAC Canada
- Employees
- RYTM N/A
- TAC N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- TAC Electric Utilities: Central
- Sector
- RYTM Health Care
- TAC Utilities
- Exchange
- RYTM Nasdaq
- TAC Nasdaq
- Market Cap
- RYTM 3.5B
- TAC 4.0B
- IPO Year
- RYTM 2017
- TAC N/A
- Fundamental
- Price
- RYTM $56.07
- TAC $10.90
- Analyst Decision
- RYTM Strong Buy
- TAC Buy
- Analyst Count
- RYTM 10
- TAC 1
- Target Price
- RYTM $66.90
- TAC $19.50
- AVG Volume (30 Days)
- RYTM 380.5K
- TAC 2.2M
- Earning Date
- RYTM 02-26-2025
- TAC 02-20-2025
- Dividend Yield
- RYTM N/A
- TAC 1.59%
- EPS Growth
- RYTM N/A
- TAC N/A
- EPS
- RYTM N/A
- TAC 0.41
- Revenue
- RYTM $112,530,000.00
- TAC $1,977,287,259.00
- Revenue This Year
- RYTM $66.58
- TAC N/A
- Revenue Next Year
- RYTM $44.63
- TAC N/A
- P/E Ratio
- RYTM N/A
- TAC $26.76
- Revenue Growth
- RYTM 81.55
- TAC N/A
- 52 Week Low
- RYTM $35.17
- TAC $5.94
- 52 Week High
- RYTM $68.58
- TAC $14.64
- Technical
- Relative Strength Index (RSI)
- RYTM 42.18
- TAC 42.02
- Support Level
- RYTM $56.03
- TAC $10.43
- Resistance Level
- RYTM $58.65
- TAC $10.84
- Average True Range (ATR)
- RYTM 1.87
- TAC 0.40
- MACD
- RYTM -0.27
- TAC 0.08
- Stochastic Oscillator
- RYTM 5.45
- TAC 45.39
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.